Wird geladen...
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma associated with poor prognosis. Implementation of high-dose cytarabine (araC) into induction therapy became standard-of-care for all newly diagnosed younger MCL patients. However, many patients relapse even a...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
BioMed Central
2014
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4094598/ https://ncbi.nlm.nih.gov/pubmed/24972933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-159 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|